SCHEMBL1230583

SCHEMBL1230583

O=C(NCCc1ccc(Br)cc1)c1sccc1Nc1ncnc2[nH]ccc12

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TTBK1 Q5TCY1 6/20 0.46
TTBK2 Q6IQ55 6/20 0.46
BTK Q06187 2/20 0.45
HDAC6 Q9UBN7 1/20 0.43
CDK2 P24941 3/20 0.42
FLT3 P36888 3/20 0.42
CCNA1 P78396 3/20 0.42
RET P07949 5/20 0.41
CCNK O75909 1/20 0.40
CDK4 P11802 1/20 0.40
CCND1 P24385 1/20 0.40
CDK6 Q00534 1/20 0.40
CDK13 Q14004 1/20 0.40
CDK12 Q9NYV4 1/20 0.40
PIM2 Q9P1W9 1/20 0.40
EGFR P00533 3/20 0.40
AURKB Q96GD4 3/20 0.40
INCENP Q9NQS7 2/20 0.40
AURKA O14965 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1231761 0.91 TTBK1 (0.48) TTBK1TTBK2BTKHDAC6CDK2
SCHEMBL1229660 0.90 BTK (0.55) TTBK1TTBK2BTKRETEGFR
SCHEMBL12900374 0.86 AKT1 (0.39) HDAC6
SCHEMBL19371933 0.85 TTBK1 (0.44) TTBK1TTBK2BTKHDAC6CDK2
SCHEMBL1229698 0.84 BTK (0.53) TTBK1TTBK2BTKCDK2FLT3
SCHEMBL1231369 0.84 BTK (0.53) TTBK1TTBK2BTKRET
SCHEMBL1231324 0.83 TTBK1 (0.45) TTBK1TTBK2CDK2FLT3CCNA1
SCHEMBL1231348 0.81 NPC1 (0.46) TTBK1TTBK2BTKCDK2FLT3
SCHEMBL1229602 0.81 RET (0.58) TTBK1TTBK2BTKHDAC6CDK2
SCHEMBL1229719 0.80 RET (0.52) TTBK1TTBK2BTKHDAC6CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011017009-A1 NOVEL AZAHETEROCYCLIC COMPOUNDS MERCK PATENT GMBH (DE) 2011-02-10 WO claimed
EP-2462141-B1 NOVEL AZAHETEROCYCLIC COMPOUNDS MERCK PATENT GMBH (DE) 2017-09-27 EP disclosed
US-9023847-B2 Azaheterocyclic compounds MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-9023847-B2 Azaheterocyclic compounds MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-20120277228-A1 Novel Azaheterocyclic Compounds MERCK PATENT GMBH (DE) 2012-11-01 US disclosed
US-20120277228-A1 Novel Azaheterocyclic Compounds MERCK PATENT GMBH (DE) 2012-11-01 US disclosed
WO-2011017009-A1 NOVEL AZAHETEROCYCLIC COMPOUNDS MERCK PATENT GMBH (DE) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120277228-A1 Novel Azaheterocyclic Compounds PCNA, MCL1, MYC TTBK1 1515/4885TTBK2 1662/4885BTK 1704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.